FOOT INFECTION-CURING DEVICE

Abstract

A foot infection-curing device (100) is provided. The device (100) consists of a frame (102) with a curved structure that aligns with a forefoot, and one or more separators (104) having one or more sponges (114) that release drugs directly to affected areas between the toes. The frame (102) and the one or more separators (104) are made of flexible material, ensuring comfort and fit for controlled drug release. The device (100) promotes hygienic application, minimizing the risk of cross-contamination. The device (100) not only simplifies maintenance process for users but also provides a more effective and targeted treatment option for various foot infections.

Specification

Description:FIELD OF INVENTION
[0001] The present disclosure relates generally to the field of drug applicator. In particular, the present disclosure pertains to a foot infection-curing device that facilitates the direct and sustained application of antifungal medication to the web spaces between the toes.

BACKGROUND
[0002] The incidence of tinea pedis, commonly known as athlete's foot, is substantial in both non-diabetic and diabetic populations. Prevalence rates are notably high, with 37.5% of non-diabetic individuals and 42.5% of diabetic individuals affected. Overall, approximately 15% to 25% of the general population experiences athlete's foot at any given time. The condition is not only widespread but also highly contagious, with the potential to spread to other individuals and different parts of the body.
[0003] Diabetic individuals are particularly susceptible to athlete's foot due to their compromised immune and vascular systems. These systems' inefficiencies predispose their feet to opportunistic fungal infections. If left untreated, these infections can progress to more severe conditions such as cellulitis and sepsis, which pose significant morbidity and mortality risks. The increased vulnerability of diabetic patients highlights the need for effective and accessible treatment methods to manage foot fungus.
[0004] Elderly patients, especially those with comorbidities like diabetes, frequently suffer from fungal infections such as intertrigo and tinea pedis. The web spaces between the toes are the most common sites for these infections. Conventional methods for treating foot fungus, predominantly involving the application of creams or ointments, face significant limitations. One major issue is that the necessity of repeated bending for application can be arduous, especially for elderly or less mobile individuals. Furthermore, the susceptibility of these creams to being washed off diminishes their duration of contact and, consequently, their effectiveness. These treatments generally lack the capability for sustained drug release, which is crucial for effective treatment over extended periods.
[0005] Commercially available toe separators are often used for orthopedic purposes, providing relief for various foot conditions by maintaining spacing between the toes. However, these separators lack the functionality of drug release, making them ineffective for treating foot fungus. Additionally, they typically do not offer adjustable spacing to accommodate different foot shapes and sizes. This limitation significantly reduces their adaptability and usefulness in addressing fungal infections.
[0006] Therefore, there is a need for a foot-infection curing drug applicator that can provide sustained medication delivery.

OBJECTS OF THE PRESENT DISCLOSURE
[0007] Some of the objects of the present disclosure, which at least one embodiment herein satisfies are as listed herein below.
[0008] An object of the present invention is to provide a foot device designed to deliver antifungal medication directly to the web spaces between the toes.
[0009] An object of the present invention is to enhance patient compliance for foot infection treatment by offering a user-friendly design that simplifies the application process.
[0010] Another object of the present invention is to create a treatment device that is adjustable to fit various foot shapes and sizes.

SUMMARY
[0011] This summary is provided to introduce a selection of concepts in a simplified form that is further described below in the detailed description section. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.
[0012] Aspects of the present invention relates to a device for treating foot-infections by improving the delivery and efficacy of antifungal medications, it addresses significant gaps in current treatment methods, enhancing patient outcomes and reducing the burden of fungal infections.
[0013] Accordingly, in an aspect, the present disclosure provides a foot infection-curing device. The device includes a frame having a curved structure configured to align with a forefoot of a user; one or more separators positioned along the frame, each to fit into web spaces between toes; and one or more sponges (114) detachably attached to the one or more separators, and configured to release a drug applied on the one or more sponges (114) directly to affected web spaces between toes of the user.
[0014] In various embodiments, the frame comprises an aperture configured to accommodate the one or more separators.
[0015] In certain embodiments, the frame and the one or more separators are formed of a flexible material selected from a group consisting of silicon rubber, thermoplastic elastomer (TPE), polyurethane (PU), ethylene vinyl acetate (EVA), polypropylene (PP) and a combination thereof.
[0016] In various embodiments, the one or more separators comprise a top portion and a bottom portion, wherein the top portion is configured to hold the one or more separators along the frame, wherein the bottom portion is configured to maintain the device's position during movement.
[0017] In certain embodiments, the one or more separators are removably fitted along the frame using a fastening means.
[0018] In various embodiments, the frame and the one or more separators are reusable.
[0019] In various embodiments, the one or more sponges are formed of a material selected from a group consisting of non-hydrophobic polyurethane, polymers, natural materials, synthetic materials, inorganic materials and a combination thereof.
[0020] In certain embodiments, the one or more sponges are pre-infused with the drug; wherein the drug may alternatively be applied to the one or more sponges prior to use.
[0021] In certain embodiments, the one or more sponges are disposable.
[0022] In certain embodiments, the drug is selected from a group consisting of an antibiotic agent, an antifungal agent, an anti-inflammatory agent and a combination thereof.
[0023] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments.

BRIEF DESCRIPTION OF DRAWINGS
[0024] The accompanying drawings are included to provide a further understanding of the present disclosure and are incorporated in and constitute a part of this specification. The drawings illustrate exemplary embodiments of the present disclosure and, together with the description, serve to explain the principles of the present disclosure.
[0025] FIG. 1 illustrates an exemplary foot infection-curing device a) device with one or more separators, b) top view, c) bottom view and d) one or more sponges attached on the one or more separators in accordance with an embodiment of the present disclosure.

DETAILED DESCRIPTION OF THE INVENTION
[0026] The following is a detailed description of embodiments of the disclosure. The embodiments are in such detail as to clearly communicate the disclosure. However, the amount of detail offered is not intended to limit the anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present invention.
[0027] All publications herein are incorporated by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
[0028] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0029] In some embodiments, numbers have been used for quantifying weight percentages, ratios, and so forth, to describe and claim certain embodiments of the invention and are to be understood as being modified in some instances by the term "about." Accordingly, in some embodiments, the numerical parameters set forth in the written description and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some embodiments of the invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0030] Various terms as used herein are shown below. To the extent a term used in a claim is not defined below, it should be given the broadest definition persons in the pertinent art have given that term as reflected in printed publications and issued patents at the time of filing.
[0031] As used in the description herein and throughout the claims that follow, the meaning of "a," "an," and "the" includes plural reference unless the context clearly dictates otherwise. Also, as used in the description herein, the meaning of "in" includes "in" and "on" unless the context clearly dictates otherwise.
[0032] Unless the context requires otherwise, throughout the specification which follow, the word "comprise" and variations thereof, such as, "comprises" and "comprising" are to be construed in an open, inclusive sense that is as "including, but not limited to."
[0033] The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein.
[0034] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. "such as") provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0035] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified.
[0036] The description that follows, and the embodiments described therein, is provided by way of illustration of an example, or examples, of particular embodiments of the principles and aspects of the present invention. These examples are provided for the purposes of explanation, and not of limitation, of those principles and of the disclosure.
[0037] It should also be appreciated that the present invention can be implemented in numerous ways, including as a system, a method or a device. In this specification, these implementations, or any other form that the invention may take, may be referred to as processes. In general, the order of the steps of the disclosed processes may be altered within the scope of the invention.
[0038] The headings and abstract of the invention provided herein are for convenience only and do not interpret the scope or meaning of the embodiments.
[0039] The following discussion provides many example embodiments of the inventive subject matter. Although each embodiment represents a single combination of inventive elements, the inventive subject matter is considered to include all possible combinations of the disclosed elements. Thus if one embodiment comprises elements a, b, and c, and a second embodiment comprises elements b and d, then the inventive subject matter is also considered to include other remaining combinations of a, b, c, or d, even if not explicitly disclosed.
[0040] The terms "foot infection-curing device" or "device" or "applicator" are used herein interchangeably with same meaning throughout the specification.
[0041] Aspects of the present invention relates to a device for treating foot-infections by improving the delivery and efficacy of antifungal medications, it addresses significant gaps in current treatment methods, enhancing patient outcomes and reducing the burden of fungal infections.
[0042] In an aspect, the disclosure provides a foot infection-curing device. The device provides a sustained dose of a drug directly to affected toes, ensuring prolonged contact and enhanced efficacy. The device further provides convenient application of drug and adequate contact time with skin, thereby improving patient compliance and mitigating risk of complications associated with untreated foot fungus, thereby reducing the necessity for invasive treatments.
[0043] Referring to FIG. 1 where the foot infection-curing device 100 is shown. The device 100 includes a frame 102 having a curved structure configured to align with a forefoot of a user. The device 100 also includes one or more separators 104 positioned along the frame 102, each to fit into web spaces between toes. The device 100 also includes one or more sponges 114 detachably attached to the one or more separators, and configured to release a drug applied on the one or more sponges 114 directly to affected web spaces between toes of the user.
[0044] In an embodiment, the frame 102 forms a core support structure of device 100, and the frame 102 is designed with a specific curvature. The curvature ensures that when the device 100 is worn, it fits snugly and securely around the front part of the foot, particularly accommodating the web spaces between the toes where fungal infections are most prevalent. The alignment of the frame 102 with the forefoot is crucial for both comfort and effectiveness. By mirroring the natural shape of the forefoot, the device 100 ensures a comfortable fit, making it suitable for extended wear. The device's 100 design consideration is especially important for elderly patients or those with limited mobility, as it simplifies the application process and reduces discomfort. Moreover, the proper alignment of the frame 102 ensures that the supporters 104, integrated into the frame 102, are positioned correctly over the web spaces between the toes. Such targeted positioning is essential for effective treatment, as it allows the medication or drug to be delivered directly to the infected areas. The curved frame 102 maintains prolonged contact between the medication and the affected skin, enhancing the overall efficacy of the treatment.
[0045] In an embodiment, the device 100 includes one or more separators 104, which are strategically positioned along the curved frame 102. The primary purpose of the separators 104 is to maintain proper spacing between the toes, which helps prevent friction and irritation that can exacerbate fungal infections. The separators 104 ensure that the medication is delivered precisely where it is needed most, targeting the infection with high accuracy. By combining the functions of toe separation and medication delivery, the device 100 offers a convenient, efficient, and effective solution for managing and treating fungal infections in the web spaces between the toes.
[0046] In an embodiment, the one or more sponges 114 are an essential component designed to deliver medication directly to the infected areas between the toes. The sponges 114 are detachably attached to the separators 104, such that they can be easily removed and replaced, ensuring both convenience and hygiene for the user. The sponges 114 are strategically positioned between the toes, where fungal or bacterial infections are most likely to occur. By adhering to the separators 104, the sponges 114 ensure that the drug is applied precisely to the affected web spaces, offering localized treatment without the need for manual application of creams or ointments.
[0047] In various embodiments, the frame 102 comprises an aperture 112 configured to accommodate the one or more separators 104. The aperture 112 in the frame 102 enhances modularity and versatility of the device 100. The aperture 112 allows for easy insertion and removal of the separators 104, making convenient to replace the separators 104 as needed. The replacement is particularly beneficial for maintaining hygiene and ensuring continuous treatment, as users can easily swap out old or used separators 104 with new ones without needing to replace the entire device 100. By integrating the separators 104 seamlessly into the frame 102, the device 100 maintains a compact and unobtrusive form, ensuring comfort for the user. The aperture 112 allow the separators 104 to function effectively without adding unnecessary bulk or complexity to the device 100.
[0048] In certain embodiments, the frame 102 is formed of a flexible material selected from a group consisting of silicon rubber, thermoplastic elastomer (TPE), polyurethane (PU), ethylene vinyl acetate (EVA), polypropylene (PP) and a combination thereof. The flexible material allows the frame 102 to conform to the natural contours of the user's foot, providing a comfortable and secure fit. Such adaptability is particularly important for accommodating different foot shapes and sizes, ensuring that the device 100 can be worn comfortably by a wide range of individuals. The flexible frame can bend and move with the foot as the user walks or performs daily activities, reducing the risk of discomfort or irritation, which is especially beneficial for users with sensitive skin or severe fungal infections, as it minimizes the potential for additional pressure or friction on the affected areas. The use of the flexible material also contributes to the device's durability and ease of use. Flexible materials are typically more resistant to cracking or breaking under stress, ensuring that the device 100 remains functional and effective over time. Moreover, the flexibility makes the device 100 easier to put on and take off, simplifying the treatment process for users, particularly those with limited mobility or dexterity.
[0049] In various embodiments, the one or more separators 104 are also formed of a flexible material selected from a group consisting of silicon rubber, thermoplastic elastomer (TPE), polyurethane (PU), ethylene vinyl acetate (EVA), polypropylene (PP) and a combination thereof.
[0050] In various embodiments, the one or more separators 104 include a top portion 106 and a bottom portion 108. The top portion 106 is configured to hold the one or more separators 104 along the frame 102. The bottom portion 108 is configured to maintain the device's 100 position during movement.
[0051] The top portion 106 not only secures the separators 104 but also plays a role in ensuring that the drug, applied to the attached sponges 114, remains correctly positioned in the web spaces between the toes, where it can effectively treat the infection. The bottom portion 108 of the separators 104 is specifically configured to stabilize the device 100, ensuring that it stays securely in place during movement. The design prevents the device 100 from shifting or becoming dislodged, allowing the user to go about their daily activities while receiving continuous treatment. Together, the top portion 106 and bottom portion 108 of the separators 104 ensure both effective drug delivery and stability of the device.
[0052] In certain embodiments, the one or more separators 104 are removably fitted along the frame 102 using a fastening means 110.
[0053] In various embodiments, the frame 102 and the one or more separators (104) are reusable. The frame 102 and the separators 104 are made from durable materials that withstand repeated use without losing functionality or integrity. The reusability of the frame 102 and the separators 104 makes the device 100 cost-effective and environmentally friendly, as users do not need to replace the entire device 100 after each treatment. Instead, they can replace only the sponges 114 used for drug dispensing as needed, ensuring sustained and efficient use over time.
[0054] In various embodiments, the one or more sponges are formed of a material selected from a group consisting of non-hydrophobic polyurethane, polymers, natural materials, synthetic materials, inorganic materials and a combination thereof.
[0055] In an embodiment, the polymers are selected from a group consisting of Poly(lactic-co-glycolic acid) (PLGA), Polycaprolactone (PCL), Polylactic acid (PLA), Polyglycolic acid (PGA), Polyethylene glycol (PEG), Polyvinyl alcohol (PVA), Polyurethane (PU), Chitosan, Gelatin, Collagen, Agarose, Cellulose acetate, Ethyl cellulose, Hydroxypropyl methylcellulose (HPMC), Sodium alginate, Pectin, Hyaluronic acid, Carboxymethyl cellulose (CMC), Polyethylene oxide (PEO), Polyvinylpyrrolidone (PVP), Polysorbate, and a combination thereof.
[0056] In an embodiment, the natural materials are selected from a group consisting of Silk fibroin, Soy protein, Whey protein, Starch, Lignin, Carrageenan, Gelatin and a combination thereof.
[0057] In an embodiment, the synthetic materials are selected from a group consisting of Poly(lactide-co-caprolactone) (PLCL), Poly(ethylene-co-vinyl acetate) (PEVA), Poly(N-isopropylacrylamide) (PNIPAM), Poly(2-hydroxyethyl methacrylate) (PHEMA), Polyacrylic acid (PAA), Poly(methyl methacrylate) (PMMA) and a combination thereof.
[0058] In an embodiment, the inorganic materials are selected from a group consisting of Calcium phosphate, Calcium carbonate, Silica, Hydroxyapatite and a combination thereof.
[0059] In one embodiment, to enhance the properties of the sponges, the sponges are formed using material combinations selected from a group consisting of Chitosan + PLGA, Gelatin + PCL, PLGA + PEG, PVA + Chitosan, Collagen + Hydroxyapatite, HPMC + Sodium alginate, PLA + PGA, PCL + PEG, Gelatin + PLA, Silk fibroin + Collagen, Chitosan + Hydroxyapatite, PVA + Gelatin, Collagen + Chitosan, Silk fibroin + PLGA, PEG + Hydroxyapatite, Polyurethane + Collagen, PCL + Gelatin, PVP + Chitosan, Ethyl cellulose + HPMC, PEG + Chitosan, Polysorbate + PVP, and PLGA + Hydroxyapatite. The materials for sponges are chosen for their ability to provide a spongy consistency, ensure prolonged skin contact, and deliver the antifungal drug in a sustained manner. By utilizing combinations of these materials, the sponges can be tailored to meet specific requirements for drug release profiles, mechanical stability, and biocompatibility.
[0060] In various embodiments, the one or more sponges 114 are pre-infused with the drug. The drug may alternatively be applied to the one or more sponges 114 prior to use. In one embodiment, the sponges 114 are already applied or infused with the drug, which when in use release the drug directly to the affected area. The pre-infusion ensures that the sponges 114 are ready for immediate use without additional preparation. In another embodiment, the sponges 114 do not come pre-infused, but instead, the drug or ointment can be applied to the sponges 114 just before use. This flexibility allows the user to prepare the sponges 114 as needed, ensuring they release the drug effectively during application.
[0061] In certain embodiments, the one or more sponges 114 are disposable.
[0062] In certain embodiments, the drug is selected from a group consisting of an antibiotic agent, an antifungal agent, an anti-inflammatory agent and a combination thereof.
[0063] In an exemplary embodiment, the device 100 further includes a disposable sponge to enhance the device's 100 functionality by promoting hygienic drug application and simplifying maintenance for users. The disposable sponges can be used to hold the drug and deliver the drug to the affected areas, ensuring a clean and controlled application. After each use, the disposable sponges can be easily removed and replaced with new ones, reducing the risk of cross-contamination between uses, which improves the overall hygiene of the device and makes it more convenient for users, as they do not have to clean or sterilize the separators 104 after each use.
[0064] While the foregoing description discloses various embodiments of the disclosure, other and further embodiments of the invention may be devised without departing from the basic scope of the disclosure. The invention is not limited to the described embodiments, versions or examples, which are included to enable a person having ordinary skill in the art to make and use the invention when combined with information and knowledge available to the person having ordinary skill in the art.


ADVANTAGES OF THE PRESENT DISCLOSURE
[0065] The device provides a non-invasive method for treating fungal infections in the web spaces of the toes, reducing the necessity for invasive treatments.
[0066] The device delivers the drug directly to the affected areas, ensuring targeted treatment and minimizing the risk of systemic side effects.
[0067] The device is user-friendly, with easy-to-use separators that can be fitted and removed using a fastening means, simplifying the maintenance process for users.
[0068] The frame of the device is made of flexible material, ensuring a comfortable fit for the user and allowing for movement without discomfort.
[0069] The device can be used to treat a range of foot infections, as the drug used can be selected from different types depending on the infection type.
[0070] The device can be customized and adjusted to fit different foot sizes and shapes, ensuring a proper and comfortable fit for each user.
, Claims:1. A foot infection-curing device (100), comprising:
a frame (102) having a curved structure configured to align with a forefoot of a user; and
one or more separators (104) positioned along the frame (102), each to fit into web spaces between toes,
one or more sponges (114) detachably attached to the one or more separators, and configured to release a drug directly to affected web spaces between toes of the user.
2. The device (100) as claimed in claim 1, wherein the frame (102) comprises an aperture (112) configured to accommodate the one or more separators (104).
3. The device (100) as claimed in claim 1, wherein the frame (102) and the one or more separators (104) are formed of a flexible material selected from a group consisting of silicon rubber, thermoplastic elastomer (TPE), polyurethane (PU), ethylene vinyl acetate (EVA), polypropylene (PP) and a combination thereof.
4. The device (100) as claimed in claim 1, wherein the one or more separators (104) comprise a top portion (106) and a bottom portion (108), wherein the top portion (106) is configured to hold the one or more separators (104) along the frame (102), wherein the bottom portion (108) is configured to maintain the device's (100) position during movement.
5. The device (100) as claimed in claim 1, wherein the one or more separators (104) are removably fitted along the frame (102) using a fastening means (110).
6. The device (100) as claimed in claim 1, wherein the frame (102) and the one or more separators (104) are reusable.
7. The device (100) as claimed in claim 1, wherein the one or more sponges (114) are formed of a material selected from a group consisting of non-hydrophobic polyurethane, polymers, natural materials, synthetic materials, inorganic materials and a combination thereof.
8. The device (100) as claimed in claim 1, wherein the one or more sponges (114) are pre-infused with the drug; wherein the drug may alternatively be applied to the one or more sponges (114) prior to use.
9. The device (100) as claimed in claim 1, wherein the one or more sponges (114) are disposable.
10. The device (100) as claimed in claim 1, wherein the drug is selected from a group consisting of an antibiotic agent, an antifungal agent, an anti-inflammatory agent and a combination thereof.

Documents